Nov. 6, 2014, 7:44 AM
- Perrigo Co. (NYSE:PRGO) acquires Belgian consumer health products maker Omega Pharma NV for €2.48B ($3.11B) plus €1.1B in debt.
- The company will finance the transaction with a combination of cash and debt. It will play 25% of the equity value via the placement of shares to Omega founder Marc Coucke.
Nov. 6, 2014, 6:35 AM
Nov. 3, 2014, 3:44 PM
Oct. 30, 2014, 9:36 AM| 1 Comment
Oct. 20, 2014, 8:56 AM
- Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NYSE:SNY) (OTCQB:SNYNF) initiate a Phase 3 clinical trial to assess the safety and efficacy of dupilumab administered concomitantly with topical corticosteroids for the treatment of adults with moderate-to-severe atopic dermatitis (AD). The 16-week randomized, double-blind, placebo-controlled multinational study will enroll ~700 patients.
- Dupilumab is a fully-human mAb that blocks IL-4 and IL-13 signalling. It was created using Regeneron's VelocImmune technology and is being co-developed with Sanofi.
- Dermatitis-related tickers: (NYSE:VRX) (NASDAQ:ANAC) (NYSE:GSK) (NYSE:PRGO)
Sep. 29, 2014, 3:57 PM
- Perrigo Co. (PRGO -0.6%) acquires a portfolio of women's healthcare products from privately-held Missouri-based Lumara Health for $82M in cash. The products generated more than $15M in top-line sales for the 12-month period ended March 31, 2014.
- Separately, Perrigo transfers a portfolio of preclinical research assets to Imago Pharmaceuticals for an undisclosed upfront payment, development-related milestones and royalties on future sales. The portfolio includes IP, drug candidates and a 500k compound CNS-focused small molecule library. It acquired the assets when it bought Elan Corp. in December 2013.
Aug. 29, 2014, 9:05 AM
- People familiar with the situation say that the Belgian OTC drug maker Omega Pharma NV has attracted interest from a number of pharmaceutical companies including Perrigo (NYSE:PRGO), Boehringer Ingelheim, Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) and Sanofi (NYSE:SNY) (OTCQB:SNYNF).
- The tab for acquiring the business could be as high as 4B euros ($5.3B).
Aug. 25, 2014, 10:18 AM
- The FDA approves Iroko Pharmaceuticals' Zorvolex (diclofenac) for the management of osteoarthritis pain. The agency cleared the NSAID for the treatment of mild-to-moderate pain in adults in October 2013.
- Related tickers: (PFE +0.1%) (MRK +0.9%) (OTCPK:BAYZF) (OTCPK:BAYRY +1.2%) (OTCQX:RHHBY +0.6%) (TEVA -0.5%) (MYL +0.8%) (PRGO -0.1%) (GSK +0.8%)
Aug. 14, 2014, 8:48 AM
- Perrigo Company (NYSE:PRGO) fiscal Q4 and full year results:
- Q4: Revenues: $1,144.2M (+18.3%); Operating Income: $197.4M (+9.6%); Net Income: $131.7M (+11.1%); EPS: $0.98 (-21.6%); Quick Assets: $805.4M (+3.3%).
- Fiscal 2014: Revenues: $4,060.8 (+14.7%); Operating Income: $567.0M (-16.5%); Net Income: $205.3M (-53.5%); EPS: $1.77 (-62.2%); CF Ops: $693.5M (+25.2%).
- Fiscal 2015 Guidance: GAAP net income: $546.1M - 586.6M; GAAP EPS: $4.05 - 4.35; non-GAAP net income: $972.0M - 1,012.5M; non-GAAP EPS: $7.20 - 7.50.
- Shares are up 4% premarket on modest volume.
Aug. 14, 2014, 8:07 AM
Aug. 13, 2014, 5:55 PM
Aug. 13, 2014, 5:30 PM
Jul. 21, 2014, 7:15 AM
- Bloomberg reports that, according to analysts, there are three ex-U.S. medical firms that should be high on the target acquisition list for tax inversion deals. Ireland-based Perrigo (NYSE:PRGO), Switzerland-based Actelion and U.K.-based Smith & Nephew Plc (NYSE:SNN) (OTCQB:SNNUF) are all attractive targets. Observers believe there will be more acquisitions consummated before Congress puts limits on the maneuvers.
- Stryker (NYSE:SYK) has been mentioned as a potential suitor for Smith& Nephew. Pfizer (NYSE:PFE) may make another run at AstraZeneca (NYSE:AZN) after the end of the cool-off period.
Jul. 11, 2014, 7:23 AM
- Sun Pharmaceutical Industries voluntarily recalls 41,127 bottles of antidepressant venlafaxine hydrochoride in the U.S. because the pills do not meet dissolution specifications. The recall is classified as Class II which means that the use of the drug may cause temporary or medically reversible adverse health consequences.
- Pfizer (PFE) recalled 104,000 bottles of the same drug several months ago after a pharmacist noticed that one of the bottles contained a heart medication. It sells in the U.S. under the brand name Effexor XR.
- Sun is also recalling 200 vials of the chemo drug gemcitabine in the U.S. due to a lack of assurance of sterility.
- Related tickers: (TEVA) (RDY) (MYL) (MNK) (PRGO)
Jun. 5, 2014, 10:36 AM
- The European Medicines Agency (EMA) reinstates the GMP certificate for India's generic drug maker Ranbaxy Laboratories' Toansa manufacturing site after the company implements corrective measures. The EMA suspended the GMP certificate in January after an on-site FDA inspection discovered significant deficiencies. An EMA inspection team concluded that there was no evidence that any drugs in the EU market containing Toansa-made ingredients were of unacceptable quality or presented a risk to patients.
- Related generic drug tickers: (TEVA) (RDY) (MYL) (MNK) (PRGO)
May. 7, 2014, 8:04 AM
PRGO vs. ETF Alternatives
Other News & PR